Editing Myopia (section)

===Medication===
[[muscarinic antagonist|Anti-muscarinic]] topical medications in children under 18 years of age may slow the worsening of myopia.<ref name="Walline">{{cite journal | vauthors = Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, Twelker JD | title = Interventions to slow progression of myopia in children | journal = The Cochrane Database of Systematic Reviews | issue = 1 | pages = CD0O6460 | date = 2020 | volume = 1 | pmid = 31930781 | pmc = 6984636 | doi = 10.1002/14651858.CD004916.pub4 }}</ref><ref>{{cite journal | vauthors = Smith MJ, Walline JJ | title = Controlling myopia progression in children and adolescents | journal = Adolescent Health, Medicine and Therapeutics | volume = 6 | pages = 133–40 | date = 2015 | pmid = 26316834 | pmc = 4542412 | doi = 10.2147/AHMT.S55834 | doi-access = free }}</ref> These treatments include [[pirenzepine|pirenzepine gel]], [[cyclopentolate|cyclopentolate eye drops]], and [[atropine]] [[eye drops]]. While these treatments were shown to be effective in slowing the progression of myopia and reducing eyeball elongation associated with the condition, side effects included light sensitivity and near blur.<ref name="Walline" /><ref>{{Cite journal |last1=Li |first1=Fen Fen |last2=Yam |first2=Jason C. |date=2019-10-04 |title=Low-Concentration Atropine Eye Drops for Myopia Progression |journal=Asia-Pacific Journal of Ophthalmology |volume=8 |issue=5 |pages=360–365 |doi=10.1097/APO.0000000000000256 |issn=2162-0989 |pmc=6784858 |pmid=31478936}}</ref>